UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2023
Commission File Number: 333-231839
CHINA SXT PHARMACEUTICALS, INC.
(Translation of registrant’s name into English)
178 Taidong Rd North, Taizhou
Jiangsu, China
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
China SXT Pharmaceuticals,
Inc. (the “Company”) is filing this report on Form 6-K to report its financial results for the six months ended September
30, 2022 and to discuss its recent corporate developments. Attached as exhibits to this report on Form 6-K are:
| |
(1) |
Management’s Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.1; |
| |
|
|
| |
(2) |
the unaudited condensed interim consolidated financial statements and related notes as of September 30, 2022 and for the six months ended September 30, 2022 and 2021 as Exhibit 99.2; |
| |
|
|
| |
(3) |
Interactive Data File disclosure as Exhibit 101 in accordance with Rule 405 of Regulation S-T. |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this current
report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that are not historical
facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited
to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,”
“forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,”
“seek,” “may,” “might,” “could” or “should,” and words of similar meaning
in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written
forward-looking statements may also be included in other materials released to the public. These statements are based on management’s
assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number
of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements,
including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition
and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission.
Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from
those set forth in the forward-looking statements.
All such forward-looking
statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements
and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation
to update any forward-looking statements to reflect events or circumstances after the date hereof.
Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: February 24, 2023
| |
China SXT Pharmaceuticals, Inc. |
| |
|
|
| |
By: |
/s/
Feng Zhou |
| |
Name: |
Feng Zhou |
| |
Title: |
Chief Executive Officer |
3
China SXT Pharmaceuticals, Inc.